Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fraunhofer IZI Granted Manufacturing Authorization for Second GMP Facility

Published: Thursday, January 23, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
Company’s cleanroom capacities shall again be expanded by mid-2015.

On 10 January 2014, the existing manufacturing authorization according to Art. 13 of the German Drug Act (AMG) of the Fraunhofer Institute for Cell Therapy and Immunology IZI was expanded to cover the first extension of the existing cleanroom facility.

After extensive qualification and inspection by the Regional Council of Saxony, the »Certificate of GMP-Compliance of a Manufacturer« was also updated. This seal of approval doubles the institute's capacities to manufacture cell-based medicinal products, or so-called »Advanced Therapy Medicinal Products« (ATMP).

Cell therapy products for clinical studies can now be produced on a total cleanroom area of over 750 m² in sixteen cleanroom class B manufacturing rooms to be operated independently.

The specific facility design allows for the parallel manufacture of several cell therapy products without the risk of mutual cross-contamination.

A separate part of the facility is furthermore specifically designed for the manufacture of products that must meet special safety requirements with respect to genetic engineering or protection against infection.

The operation of two separate and independent facilities provides maximum flexibility and continuity in the manufacturing processes, especially for bridging regularly scheduled maintenance periods.

A major part of the new facility is already booked out with manufacturing projects for various different clinical studies up to Phase III.

The staff consisting of 61 qualified employees currently handles both GMP facilities, the associated projects and the comprehensive quality assurance system. These professionals have profound expertise in the production and quality control of autologous and allogeneic cell therapy products, process development, and the validation of production processes as well as quality controls.

The cleanroom capacities of the Fraunhofer IZI shall again be expanded with a third construction section by mid-2015 to meet the continuously growing demand in this business sector.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos